Information  X 
Enter a valid email address

C4X Discovery (C4XD)


Thursday 02 December, 2021

C4X Discovery

Board Change

RNS Number : 2929U
C4X Discovery Holdings PLC
02 December 2021

C4X Discovery Holdings plc


("C4XD", "C4X Discovery" or the "Company")


Board Change

C4XD strengthens Board with the appointment of Dr Mario Polywka as Harry Finch steps down


2 December 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces the appointment of Dr Mario Polywka as a Non-Executive Director to the Board of Directors effective from 1 December 2021.  Dr Polywka replaces Harry Finch, Non-Executive Director who has confirmed that he will be stepping down from the Board of Directors following the Annual General Meeting which is expected to be held in January 2022.


Mario joins C4XD with more than 20 years' experience in leadership roles across the biotech industry.  Mario brings strong operational, commercial, strategic and drug discovery expertise to the Board.  Hewas Chief Operating Officer of Evotec SE for 12 years,where he was involved with transactions worth more than
$1.0 billion within Evotec and Oxford Asymmetry International, prior to becoming a Member of the Evotec Supervisory Board.  In addition, he holds a number of Non-Executive Board Director positions in biotech companies including Exscientia, Forge, Blacksmith Medicines and Orbit Discovery. Mario studied chemistry at Oxford University, where he also completed a DPhil with Professor Steve Davies and a postdoc with the late Professor Sir Jack Baldwin. He is a Fellow of the Royal Society of Chemistry and has published a number of papers in leading publications.


Eva-Lotta Allan, Chairman of C4X Discovery, said: " I'm delighted to welcome Mario to C4XD. With his highly successful career in biotech and his broad industry expertise, I am confident he will contribute significantly to the C4XD Board of Directors, and I look forward to working with Mario on the Board " .


" I would very much like to take th is opportunity to   thank Harr y on behalf of the Board   for his guidance and deep commitment to C4XD for the last 11 years. He has been an invaluable source of support , not only to the Board, but also to the scientific and commercial teams throughout the Company's formative years and we wish him well with his new endeavour ."


Dr Mario Polywka commented: "I am excited to be joining C4XD at this important time in the Company's growth.  With two recent deals with leading pharmaceutical companies, C4XD has clearly demonstrated the strength of its science and its ability to commercialise it.  The C4XD Board and team are entrepreneurial, have deep R&D expertise and are driven, and I am looking forward to working closely with them ."


Additional Disclosures


The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules of Companies.


Dr Mario Polywka (aged 58) holds, or has held, the following current and former directorships in the past five years:


Current Directorships

Former Directorships in the past five years

Blacksmith Medicines Inc.

Aptuit (Oxford) Limited

Evotec SE

Aptuit (Potters Bar) Limited

Exscientia Plc

Cyprotex Discovery Limited

Forge Therapeutics Inc.

Cyprotex Limited

Obit Discovery Ltd

Euprotec Limited

Orbit Discovery Group Ltd

Evotec (UK) Limited

Exscientia AI Limited

Panion Limited

Pharminox Ltd

T-Cypher Bio Limited


Save as set out above, no further information regarding Dr Mario Polywka is required to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies.


- Ends -




C4X Discovery Holdings

Mo Noonan, Communications

+44 (0)787 6444977

Panmure Gordon (UK) Limited (NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

+44 (0)20 7886 2500

Rupert Dearden (Corporate Broking)

C4X Discovery Media - Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700


Notes to Editors:


About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.


We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t